However, recent literatures reported that patients with high expression levels in PD-1 and PD-L1 had better prognosis in breast cancer, glioblastoma, metastatic melanoma, colorectal cancer, pulmonary squamous cell carcinoma, and ovarian cancer [15, 17–20]. This evidence concerns the gene CD274 and breast carcinoma.